Fostering continuous quality improvement in a European rare disease network: Where are we now?
Linde Margriet van der Kamp1,2,3, Sara Román Galdrán4,5, Willemijn F E Irvine4,5,6
1European Reference Network for Rare Inherited and Congenital Anomalies (ERNICA), Rotterdam, The Netherlands. L.vanderkamp@erasmusmc.nl.
No abstract available in PubMed .
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
05:32High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia
Published on: January 19, 2022
Related Concept Videos
Continuous Renal Replacement Therapy
Chronic Kidney Disease III: Interprofessional Care
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinically Relevant Drug Product Specifications: Methods of Establishment
